

EDUCATION

University of Illinois at Chicago.

PhD – Microbiology & Immunology
Fall 2006.

University of Illinois at Chicago.

MS – Mathematics & Computer Science
Summer 2002.

Anna University, Chennai, India.

B.Tech – Industrial Biotechnology
Spring 1998.

EXPERIENCE

California Institute of Technology.

Postdoctoral Scholar (Feb 2007 – present).

- Identification of Ubiquitin proteasome system components in ER α turnover.

University of Illinois at Chicago.

Research Specialist (2005 – 2007).

- Mechanism of apoptosis induction and cancer cell specificity by transcriptional inhibitor ARC.
- Effect of transcriptional inhibitor ARC on *p53* function.
- Identification of a small molecule inhibitor of oncogenic transcription factor *FoxM1*.

Visiting Research Specialist (2002 – 2005).

- Identification of ARC, a novel small molecule transcriptional inhibitor.
- Effect of *E2F1* over-expression: *p21* mediated cell-cycle arrest.
- Effect of *PPAR- γ* agonist Pioglitazone on various cancer cell lines.
- Development of a web-based system for identifying transcription factor binding sites in the promoter regions on a genomic scale.
- Elucidating the effects of *p53* and *c-myc* over-expression by Microarray Analysis.

Research Assistant (1999 – 2002).

- Identification of alternate transcripts of *p21*
- Cloning of different fragments of *IG20* gene into mammalian expression vector.

Teaching Assistant (Spring 2001, Fall 2001 & Spring 2002).

- Taught lab courses on Introductory Biology, Comparative Vertebrate Anatomy and Comparative Physiology at the Department of Biological Sciences.

TAC Ltd, Chennai, India.

Bioprocess Engineering Trainee (1998 – 1999).

- Production of Biopesticides using *Bacillus thuringiensis* subsp. *galleriae* and *Bacillus thuringiensis* subsp. *israelensis* and *Bacillus sphaericus*.

SPIC Bioprocess Lab, Chennai, India.

Undergraduate Research Intern (1997 – 1998).

- Effect of Carbon and Nitrogen Components on the Insecticidal Crystal Protein Production of *Bacillus thuringiensis* subsp. *galleriae*.

Indian Institute of Chemical Biology, Calcutta, India.

Summer Intern (1996).

- Effect of administration of Thyroid Hormone to Hypothyroid rats: Age-related changes in the sensitivity of *actin* expression in developing brain.

PUBLICATIONS

- **Radhakrishnan SK** and Gartel AL. FOXM1: The Achilles' heel of cancer? *Nat Rev Cancer*, 2008; 8 (3), Published Online.
- **Radhakrishnan SK**, Bhat UG, Halasi M and Gartel AL. P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents. *Oncogene*, 2008; 27 (9), 1306-1309.
- **Radhakrishnan SK***, Halasi M*, Bhat UG, Kurmasheva RT, Houghton PJ and Gartel AL. Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells. *Oncogene*, 2008; 27 (5), 694-699. (*Contributed equally).
- Nekhai S, Bhat UG, Ammosova T, **Radhakrishnan SK**, Jerebtsova M, Niu X, Foster A, Layden TJ and Gartel AL. A novel anti-cancer agent ARC antagonizes HIV-1 and HCV. *Oncogene*, 2007; 26 (26), 3899-3903.
- **Radhakrishnan SK**, Bhat UG, Hughes DE, Wang IC, Costa RH and Gartel AL. Identification of a chemical inhibitor of the oncogenic transcription factor Forkhead Box M1. *Cancer Research*, 2006; 66 (19), 9731-9735. (Featured in the section *Cancer Research Highlights: Selected articles from this issue*).
- **Radhakrishnan SK** and Gartel AL. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits anti-angiogenic activity. *Cancer Research*, 2006; 66 (6), 3264-3270. (Featured in the section *Cancer Research Highlights: Selected articles from this issue*).
- **Radhakrishnan SK** and Gartel AL. CDK9 phosphorylates p53 on serine residues 33, 315 and 392. *Cell Cycle*, 2006; 5 (5), 519-521.
- **Radhakrishnan SK*** and Kamalakaran S. Pro-apoptotic role of NF- κ B: Implications for cancer therapy. *Biochim Biophys Acta – Rev on Cancer*, 2006; 1766 (1), 53-62. (*Corresponding Author).
- **Radhakrishnan SK*** and Kamalakaran S. Time to harness the pro-apoptotic property of NF κ B? *Nat Rev Cancer*, 2006; 6 (1), Published Online. (*Corresponding Author).
- **Radhakrishnan SK**, Gierut J and Gartel AL. Multiple alternate p21 transcripts are regulated by p53 in human cells. *Oncogene*, 2006; 25 (12), 1812-1815.
- Gartel AL and **Radhakrishnan SK**. Lost in Transcription: p21 repression, mechanisms and consequences. *Cancer Research*, 2005; 65 (10), 3980-3985.
- **Radhakrishnan SK** and Gartel AL. The PPAR- γ agonist Pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. *Cell Cycle*, 2005; 4 (4), 582-584.
- Kamalakaran S*, **Radhakrishnan SK*** and Beck WT. Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites. *J Biol Chem* 2005; 280 (22), 21491-21497. (*Contributed equally).

- Gartel AL, **Radhakrishnan SK**, Serfas MS, Kwon YH and Tyner AL. A novel p21^{WAF1/CIP1} transcript is highly dependent on p53 for its basal expression in mouse tissues. *Oncogene* 2004; 23 (49), 8154-8157.
- **Radhakrishnan SK**, Layden TJ and Gartel AL. RNA interference as a new strategy against viral hepatitis. *Virology* 2004; 323 (2), 173-181.
- **Radhakrishnan SK**, Feliciano CS, Najmabadi F, Haegebarth A, Kandel ES, Tyner AL and Gartel AL. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. *Oncogene* 2004; 23 (23), 4173-4176.

PATENTS

- Gartel AL and **Radhakrishnan SK**. Nucleoside Compounds and Methods of use thereof. *U.S. Patent application # 11/912,820 (Oct 26, 2007) and International patent application # PCT/US2006/015834 (Apr 26, 2006)*.
- Gartel AL and **Radhakrishnan SK**. Identification and use of agents that modulate Oncogenic Transcription agent activity. *U.S. Patent application # 11/865,410 (Oct 1, 2007)*.

MEMBERSHIPS

- AACR (American Association for Cancer Research)
- AAAS (American Association for the Advancement of Science)
- Sigma Xi, The Scientific Research Society

GRANT SUPPORT

- **Department of Defense Breast Cancer Research Program**
Multidisciplinary postdoctoral award (\$410,451; Aug 2007-Aug 2010)
Identification of Ubiquitin System Components Involved in Ligand-Dependent Turnover of Estrogen receptor.